Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke (ENCHANTED)
Source: View publication →
In patients with acute ischemic stroke, low-dose alteplase failed to establish non-inferiority compared to standard-dose alteplase regarding the composite of death or disability at 90 days, despite significantly reducing the risk of symptomatic intracranial hemorrhage.
Key Findings
Study Design
Study Limitations
Clinical Significance
Because low-dose alteplase did not achieve the prespecified non-inferiority margin for functional outcomes, the 0.9 mg/kg dose remains the definitive global standard of care for acute ischemic stroke. However, the trial robustly demonstrated that 0.6 mg/kg alteplase effectively halves the risk of symptomatic intracranial hemorrhage. Consequently, while standard dosing should be used routinely, the low-dose regimen remains a rational alternative for highly selected patients perceived to be at an exceptionally high risk for hemorrhagic complications, and it continues to be the approved standard in Japan.
Historical Context
The standard intravenous alteplase dose of 0.9 mg/kg was established by the landmark NINDS trial in 1995. Over time, concerns regarding the 6% rate of symptomatic intracranial hemorrhage observed in NINDS led to exploratory use of lower doses, notably in Japan, where a 0.6 mg/kg dose was approved following the uncontrolled J-ACT study in 2006. The ENCHANTED trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study) was designed as a massive 2x2 factorial trial to definitively answer two major ongoing stroke controversies: the optimal dose of alteplase (published in 2016) and the safety/efficacy of early intensive blood pressure lowering versus guideline-recommended targets (published later in 2019 in The Lancet). The 2016 alteplase arm results decisively resolved the dosing debate in Western guidelines by showing that the safety benefits of low-dose alteplase come at an unacceptable trade-off in overall functional recovery.
Guided Discussion
High-yield insights from every perspective
How does alteplase act on the coagulation cascade at the molecular level, and what is the mechanistic rationale for hypothesizing that a lower dose could improve net outcomes in acute ischemic stroke?
Key Response
Alteplase is a recombinant tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin, initiating local fibrinolysis. The hypothesis for a lower dose (0.6 mg/kg) was that it would still achieve sufficient thrombolysis while mitigating off-target blood-brain barrier degradation and systemic coagulopathy, thereby reducing the rate of symptomatic intracranial hemorrhage (sICH).
When consenting a patient for thrombolysis, how do you explain the trade-off between symptomatic intracranial hemorrhage (sICH) and overall functional outcome given the ENCHANTED trial results?
Key Response
Residents must communicate that while low-dose alteplase significantly reduces the risk of sICH, it failed to show non-inferiority for preventing death or disability at 90 days. Therefore, standard-dose (0.9 mg/kg) remains the standard of care because maximizing the chance of functional independence is the primary clinical objective, even if it carries a slightly higher risk of bleeding.
How does the predominantly Asian demographic of the ENCHANTED trial impact the interpretation of the results, considering the higher prevalence of intracranial atherosclerotic disease (ICAD) in this population compared to Western cohorts?
Key Response
Fellows should recognize that stroke etiology affects treatment response. Asian populations have higher rates of ICAD, which often features rigid, platelet-rich thrombi that may be more resistant to lower doses of thrombolytics compared to cardioembolic soft clots. This pathophysiological difference might explain why the lower dose failed to achieve non-inferiority in functional outcomes despite lower bleeding rates.
Despite ENCHANTED establishing the superiority of standard-dose alteplase for functional outcomes, are there specific edge-case scenarios where you might still consider low-dose alteplase off-label, and how would you defend this choice?
Key Response
Attendings often navigate gray areas. A clinician might consider low-dose alteplase in a patient with an exceptionally high risk of hemorrhage (e.g., severe cerebral amyloid angiopathy, borderline coagulopathy, or recent minor surgery) where standard-dose is strictly contraindicated, prioritizing a reduced sICH risk while accepting potentially lower recanalization efficacy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ENCHANTED trial used a non-inferiority margin of 1.14 for the odds ratio of death or disability. How does the selection of this specific margin influence the trial's validity, and what are the statistical challenges in defining an 'acceptable' loss of efficacy?
Key Response
Setting a non-inferiority margin is subjective and highly scrutinized. A margin of 1.14 implies a willingness to accept up to a 14 percent relative increase in the odds of death or disability in exchange for a lower bleeding risk. If the margin is too wide, an inferior drug may be adopted; if too narrow, a genuinely safer alternative may be rejected.
As an editor, how would you evaluate the potential bias introduced by the open-label design of ENCHANTED on the primary endpoint (90-day modified Rankin Scale), even with blinded outcome assessment?
Key Response
Editors must critically appraise trial design flaws. Even with central blinded assessment of the mRS, open-label administration means local clinicians and patients know the dose. This can influence concurrent medical management, rehabilitation intensity, and reporting of subjective symptoms, potentially biasing the primary functional outcome assessment and undermining the internal validity.
In light of ENCHANTED failing to prove non-inferiority for low-dose alteplase, how should current AHA/ASA guidelines articulate the strength of recommendation for 0.9 mg/kg, and should any regional exceptions be formalized?
Key Response
The AHA/ASA maintains a Class I (Level of Evidence A) recommendation for standard-dose (0.9 mg/kg) alteplase. The committee must use ENCHANTED to reinforce that low-dose (0.6 mg/kg) is not recommended as a broad substitute to reduce bleeding risk, while explicitly addressing that in certain regions like Japan, 0.6 mg/kg remains standard due to distinct population-specific regulatory approvals (J-ACT trial).
Clinical Landscape
Noteworthy Related Trials
NINDS Trial
Tested
Intravenous alteplase (t-PA) 0.9 mg/kg
Population
Patients with acute ischemic stroke within 3 hours of symptom onset
Comparator
Placebo
Endpoint
Favorable outcome at 3 months (global statistic of 4 scales)
ECASS III Trial
Tested
Intravenous alteplase 0.9 mg/kg
Population
Patients with acute ischemic stroke 3 to 4.5 hours after symptom onset
Comparator
Placebo
Endpoint
Disability at 90 days (mRS score of 0 or 1)
IST-3 Trial
Tested
Intravenous alteplase 0.9 mg/kg
Population
Patients with acute ischemic stroke within 6 hours of onset, including many aged over 80 years
Comparator
Open-label control (standard care)
Endpoint
Proportion of patients alive and independent at 6 months (Oxford Handicap Scale score 0-2)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis